Press Releases 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 FDA Grants Priority Review for Eagle Pharmaceuticals’ Ryanodex NDA for the Treatment of Exertional Heat Stroke 3/27/17 Eagle Pharmaceuticals Announces Three New Patents Issued for Bendeka 3/21/17 Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors 3/16/17 Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results 3/1/17 Eagle Pharmaceuticals’ Pemetrexed NDA Accepted for Filing by the FDA 2/28/17 Eagle Pharmaceuticals Announces 11th Patent Issued for Bendeka 2/28/17 Eagle Pharmaceuticals Announces New Patents Issued for Bendeka 2/21/17 Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2016 Financial Results on March 1, 2017 2/16/17 Eagle Pharmaceuticals to Present at 2017 RBC Capital Markets Global Healthcare Conference 2/13/17 Eagle Pharmaceuticals Completes NDA Submission for Ryanodex for Exertional Heat Stroke to FDA 1/23/17 Pagination First page Previous page Page 1 Page 2 Current page 3 Page 4 Next page Last page
